

Gene Editing Market Expected to Reach \$7.4 Billion by 2031 | CAGR of 6.7%

WILMINGTON, DELAWARE, UNITED STATES, April 24, 2024

/EINPresswire.com/ -- <u>Gene editing</u> <u>market</u> was valued at \$3.9 billion in 2021, and is estimated to reach \$7.4 billion by 2031, growing at a CAGR of 6.7% from 2022 to 2031. Gene editing also known as genome editing, is a field of study that aims to modify genes in live animals in order to better understand gene function and create treatments for hereditary and acquired disorders. In many different types of



cells and species, genome editing can be used to fix, introduce, or delete practically any DNA sequence. While DNA editing techniques have been around for decades, new ways have made it faster, cheaper, and more efficient. The revelation that a broken portion of DNA in a gene stimulates a cell's repair system to patch the split together led to the development of genome editing. Researchers can use genome editing to replicate the natural process of DNA repair. Zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and meganucleases are advanced genome editing technologies based on proteins. Another approach is CRISPR/Cas9, which stands for clustered regularly interspaced short palindromic repeats.

ThermoFischer Scientific Inc., GE Healthcare, Merck KGaA, OriGene Technologies, Addgene, Precision Biosciences, Allele Biotech, CRISPR Therapeutics, Bio-Rad, Takara Bio

000 0000000 0000000 https://www.alliedmarketresearch.com/purchase-enquiry/11338

On the basis of technology, the gene editing market analysis is bifurcated into zinc finger nucleases, transcription activator-like effector-based nucleases, crispr-cas9 gene editing,

restriction enzymes, and others. The others segment is further classified into homing endonucleases or mega nucleases and antisense technology. The crispr-cas9 gene editing segment dominated the market in 2021 with a revenue of \$1,522.25 million and is expected to grow the gene editing industry with the highest CAGR of 7.9%. Growth of the segment is attributed to its application for drug discovery and identifying cancer market.

Depending on application, the gene editing market share is segmented into gene editing, cell line engineering, animal genetic engineering, plant genetic engineering, drug development, and others. The others segment is further classified into bioenergy, diagnosis, cell and gene therapies, microorganisms genetic engineering, drug discovery, GMO (genetically modified organisms), vaccine development, and basic research. The gene editing segment dominated the market in 2021 with a revenue of \$1,123.16 million and is expected to grow with the highest CAGR of 8.2%. Growth of the segment is attributed to surge in clinical diagnosis and medical research.

0000000 000000 000000 https://www.alliedmarketresearch.com/request-sample/11338

By end user, the gene editing market size is fragmented into biotechnology & pharmaceutical companies, academic & government research institutes, and contract research organizations. The biotechnology and pharmaceutical companies segment dominated the market in 2021 with a revenue of \$2,311.49 million. In gene editing market size, growth of the largest growing segment is attributed to increase in funding in R&D for drug development and cancer treatments. Academic and government institutes are expected to grow with the highest CAGR of 7.2% during the forecast period.

Powered with Complimentary Analyst Hours and Expert Interviews with Each Report

Comprehensive quantitative and qualitative insights at segment and sub-segment level

Covid 19 impact trends and perspective

Granular insights at global/regional/country level

Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment

Blanket coverage on competitive landscape

Exhaustive coverage on 'Strategic Developments' registered by leading players of the market

AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.

Explore More Report: Gene Editing Market: <u>https://www.alliedmarketresearch.com/gene-editing-market-A10973</u> Healthcare Gamification market: <u>https://www.alliedmarketresearch.com/healthcare-gamification-market-A10988</u> Indirect Calorimeter Market: <u>https://www.alliedmarketresearch.com/indirect-calorimeter-market-A10996</u> Intrauterine Devices Market: <u>https://www.alliedmarketresearch.com/intrauterine-devices-market-A10999</u>

David Correa Allied Market Research +1 503-894-6022 email us here Visit us on social media: Facebook Twitter LinkedIn Other

This press release can be viewed online at: https://www.einpresswire.com/article/706111128

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire[™], tries to define some of the boundaries that are reasonable

in today's world. Please see our Editorial Guidelines for more information. © 1995-2024 Newsmatics Inc. All Right Reserved.